Medivolve will host a webinar Monday, February 22nd at 1 pm ET with medical advisor Dr. Glenn Copeland to discuss Collection Sites telehealth strategy.
After successful operational results from its Collection Sites subsidiary, which includes the sale of 73,973 tests at an average price of $96 in January, Medivolve is initiating an investor awareness campaign.
Medivolve will host a webinar Monday, February 22nd at 1 pm ET with medical advisor Dr. Glenn Copeland to discuss Collection Sites telehealth strategy. Further, Tim Shelburn is stepping down from his executive role at Collection Sites.
Medivolve Enters into Agreement to Acquire Karland Health, Enabling its Wholly Owned Subsidiary, Collection Sites, to Expand Services Beyond COVID-19 Testing with Telehealth and Remote Patient Monitoring
Medivolve Also Strengthens its Balance Sheet via Shares for Debt Settlements.
Collection Sites Provides Update With January Sales of 73,973 Tests at an Average Price of $96 per Test
To date Collection Sites has launched a total of 62 sites across its network with additional new openings in Texas, Florida, and North Carolina. Further, Medivolve will host a webinar today, Thursday, February 4th at 1 pm ET.
Medivolve Enters Into Agreement to Acquire 100% of Noble Bioscience Corp. and Its Agency Rights to Nuturell’s COVID- 19 Surface Shield Technology
Nuturell’s non-toxic silver surface shield technology is a COVID-19 disinfectant that convertsinto a protective shield when air dry, killing the coronavirus among other pathogens for up to 90 days after only ~30 seconds of contact. Further, Medivolve will host a webinar Thursday, February 4 th at 1 pm ET.
Medivolve will host a webinar Thursday, February 4th at 1 pm ET. This includes an overview of Collection Sites’ network growth and a presentation from the UCLA researchers behind the Marvel Diagnostics innovative BlowFISH Technology for the detection of the presence of the COVID-19 virus.
Medivolve Announces Investment Into Marvel Diagnostics and Its Non-Invasive Exhaled Breath Diagnostic Technology
Marvel Diagnostics innovative BlowFISH technology offers the potential for a a simple,
inexpensive, non-invasive, massively-deployable, rapid diagnostic or sentinel system for detecting respiratory illness and airborne viral threats.
Collection Sites Continues Expansion With Launch of New COVID-19 Testing Sites in Florida, Virginia and Texas
THIS NEWS RELEASE IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES